Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

Willem Jan Fokkink, David Falck, Tom C.M. Santbergen, Ruth Huizinga, Manfred Wuhrer, Bart C. Jacobs

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
16 Downloads (Pure)


Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features ( galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.
Original languageUndefined/Unknown
JournalPLoS One (print)
Issue number10
Publication statusPublished - 2015

Research programs

  • EMC MM-02-72-02
  • EMC MM-04-44-02

Cite this